Total Payments
$724,318
2024 Payments
$16,986
Companies
47
Transactions
848
Medicare Patients
2,857
Medicare Billing
$198,045
Payment Breakdown by Category
Other$416,299 (57.5%)
Consulting$177,432 (24.5%)
Travel$95,606 (13.2%)
Food & Beverage$28,508 (3.9%)
Research$6,405 (0.9%)
Education$68.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $325,789 | 108 | 45.0% |
| Consulting Fee | $177,432 | 44 | 24.5% |
| Travel and Lodging | $95,606 | 254 | 13.2% |
| Honoraria | $30,775 | 27 | 4.2% |
| Current or prospective ownership or investment interest | $28,835 | 15 | 4.0% |
| Food and Beverage | $28,508 | 369 | 3.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $27,900 | 5 | 3.9% |
| Unspecified | $6,405 | 19 | 0.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.4% |
| Education | $68.80 | 6 | 0.0% |
Payments by Type
General
$717,913
829 transactions
Research
$6,405
2 transactions
Ownership
$0
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $135,041 | 146 | $0 (2024) |
| Janssen Biotech, Inc. | $118,676 | 150 | $0 (2024) |
| UroGPO LLC | $88,574 | 62 | $0 (2020) |
| Dendreon Pharmaceuticals LLC | $79,955 | 65 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $43,966 | 74 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $40,635 | 39 | $0 (2024) |
| SN Holdings, LLC | $37,326 | 69 | $0 (2024) |
| Merck Sharp & Dohme LLC | $36,238 | 34 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $34,941 | 33 | $0 (2017) |
| Myovant Sciences Inc. | $34,041 | 27 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,986 | 29 | Janssen Biotech, Inc. ($7,106) |
| 2023 | $54,993 | 63 | Janssen Biotech, Inc. ($15,124) |
| 2022 | $58,500 | 77 | SN Holdings, LLC ($14,411) |
| 2021 | $76,724 | 70 | Janssen Biotech, Inc. ($31,281) |
| 2020 | $48,246 | 50 | Bayer HealthCare Pharmaceuticals Inc. ($13,193) |
| 2019 | $104,151 | 164 | Astellas Pharma US Inc ($36,763) |
| 2018 | $153,689 | 203 | Astellas Pharma US Inc ($44,459) |
| 2017 | $211,030 | 192 | UroGPO LLC ($69,039) |
All Payment Transactions
848 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $116.71 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $164.57 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $98.67 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $149.20 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $49.50 | General |
| Category: Oncology | ||||||
| 07/08/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $49.50 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $384.96 | General |
| Category: Oncology | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $84.57 | General |
| Category: Oncology | ||||||
| 04/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 04/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $161.28 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $188.15 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $617.38 | General |
| Category: Oncology | ||||||
| 04/03/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 03/31/2024 | Great Lakes Medical Services, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Stock option | $29.00 | General |
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,450.00 | General |
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 02/13/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $59.07 | General |
| Category: Oncology | ||||||
| 02/02/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: HORMONE THERAPY | ||||||
| 01/24/2024 | Great Lakes Medical Services, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Stock option | $800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Xpert Bladder | Cepheid | $6,405 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 543 | 892 | $293,981 | $42,299 |
| 2022 | 11 | 675 | 1,123 | $304,873 | $52,046 |
| 2021 | 9 | 827 | 1,366 | $305,880 | $54,974 |
| 2020 | 11 | 812 | 1,189 | $286,100 | $48,725 |
Total Patients
2,857
Total Services
4,570
Medicare Billing
$198,045
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 134 | $201,000 | $16,741 | 8.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 130 | 193 | $31,459 | $12,551 | 39.9% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 14 | 16 | $14,880 | $3,014 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 28 | $6,384 | $2,428 | 38.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 53 | $6,812 | $2,249 | 33.0% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 72 | 83 | $7,470 | $1,464 | 19.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 11 | 11 | $2,675 | $1,178 | 44.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 84 | 108 | $2,160 | $907.20 | 42.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 31 | $13,000 | $837.01 | 6.4% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 128 | 192 | $3,840 | $580.30 | 15.1% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 35 | 43 | $4,300 | $349.22 | 8.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 17 | 129 | $193,500 | $18,052 | 9.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 162 | 246 | $39,471 | $15,436 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 48 | $10,748 | $4,640 | 43.2% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 18 | 22 | $20,460 | $4,539 | 22.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 18 | 71 | $9,126 | $3,790 | 41.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2022 | 91 | 115 | $10,350 | $2,056 | 19.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 18 | 27 | $4,158 | $1,104 | 26.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 18 | 32 | $5,120 | $893.46 | 17.5% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2022 | 151 | 248 | $4,960 | $761.37 | 15.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 99 | 144 | $2,880 | $424.53 | 14.7% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 35 | 41 | $4,100 | $350.60 | 8.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 204 | 341 | $44,330 | $21,859 | 49.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 18 | 126 | $189,000 | $17,407 | 9.2% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 22 | 28 | $26,040 | $5,224 | 20.1% |
About Dr. Richard Harris, M.D
Dr. Richard Harris, M.D is a Urology healthcare provider based in Melrose Park, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346290673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Harris, M.D has received a total of $724,318 in payments from pharmaceutical and medical device companies, with $16,986 received in 2024. These payments were reported across 848 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($325,789).
As a Medicare-enrolled provider, Harris has provided services to 2,857 Medicare beneficiaries, totaling 4,570 services with total Medicare billing of $198,045. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Melrose Park, IL
- Active Since 05/10/2006
- Last Updated 10/01/2019
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1346290673
Products in Payments
- PROVENGE (Drug) $114,896
- XTANDI (Drug) $88,322
- ERLEADA (Drug) $80,148
- Erleada (Drug) $70,003
- ORGOVYX (Drug) $42,320
- Xtandi (Drug) $40,497
- Nubeqa (Drug) $21,593
- Xofigo (Drug) $19,932
- PYLARIFY (Drug) $11,181
- GeneXpert (Medical Supply) $6,405
- Enzalutamide (Drug) $5,331
- FOUNDATIONACT (Device) $3,256
- Axumin (Drug) $3,222
- Non-Covered (Drug) $2,441
- RUBRACA (Drug) $2,437
- JEVTANA (Drug) $1,854
- LYNPARZA (Biological) $1,521
- SUTENT (Drug) $1,504
- SpaceOAR (Device) $1,224
- ADSTILADRIN (Biological) $1,110
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Melrose Park
Dr. Laurie Bachrach, M.d, M.D
Urology — Payments: $3,106
Urology $3,106
Stephen Hurley, D.o, D.O
Urology — Payments: $2,523
Urology $2,523
Dr. Steven Dritz, M.d, M.D
Urology — Payments: $2,337
Urology $2,337
Dr. Melanie Adamsky, M.d, M.D
Urology — Payments: $1,255
Urology $1,255
Faramarz Eghrari, M.d, M.D
Urology — Payments: $30.59
Urology $30.59
Dr. Biswamay Ray, M.d, M.D
Urology
Urology